Smoking CessationPhase 2/3Smart-TR01NCT03740490
Smartphone Based Smoking Cessation Intervention
A Phase 2/3 study testing Smart-T + NRT and QuitGuide + NRT in people with Smoking Cessation, run by University of Oklahoma at 1 site in United States.
Trial summary
Smoking is becoming increasingly concentrated among individuals with the lowest levels of income, education, and occupational status. In fact, smoking rates in the United States among people living below the poverty line is nearly twice as high as those above the poverty threshold. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Smoking Cessation
- What is being tested?
- Smart-T + NRT and QuitGuide + NRT
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 454 participants
- Where
- 1 siteUnited States
- Study dates
- 26 Aug 2019to 17 Nov 2023
- Phase
- Phase 2/3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- earn a score ≥ 4 on the Rapid Estimate of Adult Literacy in Medicine-Short Form (REALM-SF) indicating > 6th grade English literacy level
- are willing to quit smoking 7 days after the baseline visit
- are ≥ 18 years of age
- have an expired CO level ≥ 8 ppm suggestive of current smoking
- are currently smoking ≥ 5 cigarettes per day
- have no contraindications to using nicotine replacement therapy (NRT)
Show all 9Show fewer
- agree to complete EMAs and CO tests on a study provided or personal smartphone
- have household income < 200% of the federal poverty guideline
- agree to complete the 26 week post-quit follow-up assessment over the phone and via EMA
Who cannot join
- cannot read, speak, and understand English
- are < 18 years of age
Trial locations and contacts
1 site in 1 country.
United States1 site
University of Oklahoma Health Sciences Center - HPRC
Oklahoma City, Oklahoma, 73104
About this study
Smoking is becoming increasingly concentrated among individuals with the lowest levels of income, education, and occupational status. In fact, smoking rates in the United States among people living below the poverty line is nearly twice as high as those above the poverty threshold. Highly flexible and low burden technology-based treatment approaches may overcome many of the barriers that have limited the use and effectiveness of traditional smoking cessation treatments among low socioeconomic status (SES) adults. Ecological momentary assessment (EMA), in which mobile devices are used to capture moment-to-moment experiences, allows for the measurement of phenomena in real-time within natural settings. Smartphone-based smoking cessation apps could offer easily accessible, highly tailored, and intensive interventions at a fraction of the cost of traditional smoking cessation counseling. The Smart-T app uses a lapse risk estimator to identify moments of heightened risk for lapse, and the algorithm tailors treatment messages in real-time based upon level of imminent smoking lapse risk and currently present lapse triggers. This study will compare smoking cessation rates for those randomized to the Smart-T app or the NCI QuitGuide app.
Read the detailed description
Smoking is becoming increasingly concentrated among individuals with the lowest levels of income, education, and occupational status. In fact, smoking rates in the United States among people living below the poverty line is nearly twice as high as those above the poverty threshold. Highly flexible and low burden technology-based treatment approaches may overcome many of the barriers that have limited the use and effectiveness of traditional smoking cessation treatments among low SES adults. Ecological momentary assessment (EMA), in which mobile devices are used to capture moment-to-moment experiences, allows for the measurement of phenomena in real-time within natural settings. Smartphone-based smoking cessation apps could offer easily accessible, highly tailored, and intensive interventions at a fraction of the cost of traditional smoking cessation counseling. The Smart-T app uses a lapse risk estimator to identify moments of heightened risk for lapse, and the algorithm tailors treatment messages in real-time based upon level of imminent smoking lapse risk and currently present lapse triggers.
The study aims are to:
Determine the impact of treatment condition (i.e., Smart-T vs. QuitGuide app; n=225 per group) on biochemically verified smoking abstinence. Hypothesis 1: Participants randomly assigned to Smart-T will have significantly higher rates of biochemically-verified abstinence than those assigned to QuitGuide at 26 weeks post-quit.
Determine the effect of Smart-T treatment messages on key lapse risk factors. Hypothesis 2: Smoking urge, stress, and cigarette availability will decline more and cessation motivation will increase more following tailored messages that target these lapse triggers in real-time (Smart-T condition) compared with similar situations wherein no messages are provided (QuitGuide condition).
EXPERIMENTAL DESIGN:
Participants (N=550) will be recruited through the TSET Health Promotion Research Center (HPRC) Tobacco Treatment Research Program (TTRP) which is directed by Dr. Darla Kendzor (Co-I). Participants will also be recruited through advertisements. Individuals seeking smoking cessation services at the TTRP will be given a verbal description of the study during their first visit, and those interested will be screened for study eligibility. Those who respond to study advertisements will complete a brief RedCap screener online (i.e., OKSmokerstudy.com), and those who qualify for the study will contacted by study staff and scheduled for a screening/baseline visit. Consistent with our previous research with low SES populations, we have limited exclusion criteria so that the sample is as broad and representative of the population as possible. Interested individuals will be included in the study if they: 1) earn a score ≥ 4 on the Rapid Estimate of Adult Literacy in Medicine-Short Form (REALM-SF)56 indicating > 6th grade English literacy level (required to complete EMAs; at least 88% of all individuals screened for our EMA studies have met this inclusion criterion), 2) are willing to quit smoking 7 days after the baseline assessment, 3) are ≥ 18 years of age, 4) have an expired CO level ≥ 7 ppm suggestive of current smoking for those who attend in person baseline visits or substantiate smoking status (e.g., produce a pack of cigarettes) during baseline assessments by sending picture of cigarettes to staff 5) are currently smoking ≥ 5 cigarettes per day, 6) have no contraindications to using NRT, 7) agree to complete EMAs and CO tests on a study provided or personal smartphone, 8) have household income < 200% of the federal poverty guideline,57 and 9) agree to complete the 26 week post-quit follow-up assessment over the phone and via EMA.
Eligible and interested individuals will be randomized to 1 of 2 groups: 1) Smart-T smoking cessation intervention plus NRT, or 2) NCI QuitGuide smoking cessation intervention plus NRT. Stratified randomization will be used to assign participants to groups based upon race, sex, and cigarettes smoked per day. Participants will be followed for 27 weeks and will attend either 1 in-person visit or complete phone-based baseline visits. Participants will be prompted to complete daily EMAs and tests of smoking status using a portable, low-cost, carbon monoxide monitor (Bedfont iCO Smokerlyzer) on 3 days each week. This data will be used to address primary (i.e., biochemically verified 7-day point prevalence abstinence at 26 weeks post-quit) and secondary outcomes (e.g., 30-day point prevalence abstinence, number of days to first lapse, longest period of smoking abstinence). Geographic location data will be captured multiple times per day to link characteristics of the present environment (e.g., proximity to tobacco outlets) with cessation-related outcomes. We have already created software that integrates the iCO sensor into our InsightTM mobile application platform.
Sub-Study Update: A sample(n=30) of American Indian/Alaska Native participants who have completed the 6 month follow-up assessment will be asked to participate in another qualitative interview designed to assess the perceived utility and cultural fit of the Smart-T App.Information gathered from these qualitative interviews will be used to culturally modify and then experimentally test a new, culturally tailored, version of the Smart-T app for AI/AN smokers who want to quit smoking. In addition, this will serve as an incredibly valuable training opportunity for an emerging Native American scientist to learn tobacco cessation, mHealth, and qualitative methods research from an interdisciplinary team of leading experts in the field.
PROPOSED PROCEDURE:
Individuals who provide informed consent and meet the study inclusion criteria will complete the baseline assessment in TTRP clinic space (the TTRP is located in Research Parkway in a building that is adjacent to the PI's office). Participants may alternatively complete the baseline assessment via phone calls with study staff. Following the baseline assessment, participants will be given instruction on how to complete phone-based EMAs and carbon monoxide assessments. All participants, regardless of condition, will be compensated for completing the baseline assessments, phone-based follow-up, and EMAs. In addition, participants will complete expired breath carbon monoxide tests using the portable iCO device 3 days per week (weeks 1-27).
Baseline and follow-up measures will assess demographic and smoking characteristics, multiple constructs that are known to be related to lapse (e.g., depression, stress, affect, social support), and document intervention effects (See Table 3 and Appendix). We will also access participant perceptions of each app feature. The Baseline process will take approximately 60-90 minutes to complete and data will be collected either on laptop/tablet computers using Questionnaire Development System (QDS) software or remotely via RedCap surveys. QDS uses a computer-administered self-interview format (i.e., ACASI), which reduces data entry errors and the need to retain paper copies of raw data. Each item appears on the computer screen while the program simultaneously reads the item (participants touch the screen to select answers only after QDS reads each item). Participants wear headphones so that others do not hear the survey items. Participants from our previous studies in similar populations, including those with no computer experience, have reported few problems using the QDS program. Staff will be available to help participants who may have difficulty. The RedCap surveys have been designed to replicate the QDS version as closely as possible. The 26 week post-quit follow-up assessment, which includes a longer EMA (i.e., 20-30 minutes) and a phone call based interview (i.e., The Treatment Improvement Survey, 10-15 minutes) that will be recorded for qualitative analysis.
Participants who own an Android smartphone (OS version 6.0 or higher) will be encouraged to download and use the study app on their own phone. Those who do not own this type of smartphone and those who do not have a data plan will be loaned a Samsung smartphone (or equivalent) for 27 weeks so that they may complete EMAs. Participants will navigate through the EMA program and enter data simply by touching the screen. The study app (i.e., Smart-T app or EMA only app) includes a "Call Staff" function/button that automatically calls study staff (e.g., if they have problems completing EMAs). The EMA app also includes a "Payment" button which, when pressed, indicates the number of EMAs that have been prompted and completed and the current level of compensation based upon the up-to-the-moment percentage of EMAs completed. Smartphones will automatically collect data when on-demand features are accessed for both the QuitGuide and Smart-T groups (e.g., number of times features are used). Use of personal vs. study provided phones will be examined as a covariate in all analyses.
IMPORTANCE OF KNOWLEDGE REASONABLY EXPECTED TO RESULT FROM THE RESEARCH:
Although many smartphone based smoking cessation apps exist, none have been developed and empirically validated via a randomized controlled trial in socioeconomically disadvantaged populations of smokers who are seeking to quit smoking. This study is the next step in a line of research that aims to develop and disseminate effective and automated treatments for smoking cessation for this underserved and understudied population. Thus, the knowledge that will be gained from this study is important. Furthermore, the Smart-T app will allow us to reach a population that frequently lacks access to traditional intervention programs, due to limited availability, income, and/or transportation, among other barriers. In addition, the proposed smartphone app is highly versatile and may be easily modified for use in other populations or communities. The risks to subjects are minimal, especially considering the protections against risks that will be implemented for this study.
- Conditions
- Smoking Cessation
- Being tested
- Smart-T + NRT, QuitGuide + NRT
- Keywords
- Smoking Cessation, Smartphone Based Smoking Cessation
- Medical subject headings
- Smoking Cessation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Smart-T + NRTCombination product
Smart-Treatment App and Nicotine Replacement Therapy
QuitGuide + NRTCombination product
NCI QuitGuide Treatment App and Nicotine Replacement Therapy
| Study group | Role | What they receive |
|---|---|---|
| Smart-T + NRT | Experimental | Smart-T provides content during the pre-quit and post-quit periods to prepare and support participants during their quit attempt. The Smart-T app contains multiple components including an EMA delivery and data transfer system, automated messages based upon EMA responses, and on-demand content. All participants will receive free nicotine replacement therapy (NRT). Receives: Combination Product: Smart-T + NRT |
| NCI QuitGuide + NRT | Active comparator | The National Cancer Institute's QuitGuide app is a free smartphone app and is one of few apps that includes many of the recommendations detailed in the Clinical Practice Guideline. The QuitGuide app aims to help smokers understand their smoking patterns and develop the skills needed to quit smoking. QuitGuide provides content during the pre-quit and post-quit periods to prepare and support participants during their quit attempt. All participants will receive free nicotine replacement therapy (NRT). Receives: Combination Product: QuitGuide + NRT |
What is being measured
The primary outcome is the main question the study is designed to answer.
Biochemically-Verified Smoking Cessation
Biochemically confirmed 7-day point prevalence abstinence using the CO criteria cutoff of ≤ 6 ppm
Measured: 27 Weeks
Secondary outcomes (4)
Change in Urge to Quit Smoking
Urge was assessed using a single ecological momentary assessment (EMA) question: "I feel the urge to smoke." Participants rated this item on a 5-point Likert scale ranging from 1 (Strongly disagree) to 5 (Strongly agree). Change scores were calculated by subtracting the pre-message rating from the post-message rating for each prompt. The possible range for the change score is -4 to +4. Higher scores indicate an increase in urge to smoke (worse outcome).
Measured: 27 weeks
Change in Stress
Stress was assessed using a single ecological momentary assessment (EMA) question: "I feel stressed." Participants rated this item on a 5-point Likert scale ranging from 1 (Strongly disagree) to 5 (Strongly agree). Change scores were calculated by subtracting the pre-message rating from the post-message rating for each prompt. The possible range for the change score is -4 to +4. Higher scores indicate an increase in stress (worse outcome).
Measured: 27 weeks
Change in Perceived Cigarette Availability
Perceived cigarette availability was assessed using a single ecological momentary assessment (EMA) question: "Cigarettes are available to me right now." Participants rated this item on a 5-point Likert scale ranging from 1 (Strongly disagree) to 5 (Strongly agree). Change scores were calculated by subtracting the pre-message rating from the post-message rating for each prompt. The possible range for the change score is -4 to +4. Higher scores indicate an increase in perceived cigarette availability (worse outcome).
Measured: 27 weeks
Change in Motivation to Quit Smoking
Motivation to quit smoking was assessed using a single ecological momentary assessment (EMA) question: "I want to quit smoking." Participants rated this item on a 5-point Likert scale ranging from 1 (Strongly disagree) to 5 (Strongly agree). Change scores were calculated by subtracting the pre-message rating from the post-message rating for each prompt. The possible range for the change score is -4 to +4. Higher scores indicate an increase in motivation to quit smoking (better outcome).
Measured: 27 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Nov 2018
- Study start26 Aug 2019
- Primary completion17 Nov 2023
- Study completion17 Nov 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Smoking CessationStudies of the same condition, open and under way.
- More trials run by University of OklahomaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2/3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 454 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Oklahoma
- Sponsor type
- University, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Sponsor
- Investigators
- Michael S Businelle, PhD, Principal investigator, University of Oklahoma
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03740490
- Sponsor's protocol ID
- 9860
- Other IDs
- R01CA221819
- Acronym
- Smart-TR01
- Status last verified
- Aug 2025
- First submitted
- 9 Nov 2018
- Last updated
- 17 Aug 2025
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Hebert ET, Kendzor DE, Vidrine DJ, Langford JS, Kezbers KM, Montgomery A, Chen M, Frank-Pearce SG, Vesely SK, Chen S, Barrett ZCW, Businelle MS. Just-in-Time Adaptive Intervention for Smoking Cessation in Low-Income Adults: A Randomized Clinical Trial. JAMA Netw Open. 2025 Aug 1;8(8):e2526691. doi: 10.1001/jamanetworkopen.2025.26691.
PubMed 40810943
Study at a glance
From the registry record, last updated by the sponsor on 17 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Smartphone Based Smoking Cessation Intervention
- ClinicalTrials.gov ID
- NCT03740490
- Acronym / sponsor ID
- Smart-TR01 / 9860
- Conditions
- Smoking Cessation
- Keywords
- Smoking Cessation, Smartphone Based Smoking Cessation
- Phase
- Phase 2/3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 454 participants (actual)
- Lead sponsor
- University of OklahomaUniversity, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Study start
- 26 Aug 2019 (actual)
- Primary completion
- 17 Nov 2023 (actual)
- Study completion
- 17 Nov 2023 (actual)
- First posted
- 14 Nov 2018 (actual)
- Results
- Posted 31 Jul 2025
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Smoking is becoming increasingly concentrated among individuals with the lowest levels of income, education, and occupational status. In fact, smoking rates in the United States among people living below the poverty line is nearly twice as high as those above the poverty threshold. Highly flexible and low burden technology-based treatment approaches may overcome many of the barriers that have limited the use and effectiveness of traditional smoking cessation treatments among low socioeconomic status (SES) adults. Ecological momentary assessment (EMA), in which mobile devices are used to capture moment-to-moment experiences, allows for the measurement of phenomena in real-time within natural settings. Smartphone-based smoking cessation apps could offer easily accessible, highly tailored, and intensive interventions at a fraction of the cost of traditional smoking cessation counseling. The Smart-T app uses a lapse risk estimator to identify moments of heightened risk for lapse, and the algorithm tailors treatment messages in real-time based upon level of imminent smoking lapse risk and currently present lapse triggers. This study will compare smoking cessation rates for those randomized to the Smart-T app or the NCI QuitGuide app.
Detailed description
Smoking is becoming increasingly concentrated among individuals with the lowest levels of income, education, and occupational status. In fact, smoking rates in the United States among people living below the poverty line is nearly twice as high as those above the poverty threshold. Highly flexible and low burden technology-based treatment approaches may overcome many of the barriers that have limited the use and effectiveness of traditional smoking cessation treatments among low SES adults. Ecological momentary assessment (EMA), in which mobile devices are used to capture moment-to-moment experiences, allows for the measurement of phenomena in real-time within natural settings. Smartphone-based smoking cessation apps could offer easily accessible, highly tailored, and intensive interventions at a fraction of the cost of traditional smoking cessation counseling. The Smart-T app uses a lapse risk estimator to identify moments of heightened risk for lapse, and the algorithm tailors treatment messages in real-time based upon level of imminent smoking lapse risk and currently present lapse triggers.
The study aims are to:
Determine the impact of treatment condition (i.e., Smart-T vs. QuitGuide app; n=225 per group) on biochemically verified smoking abstinence. Hypothesis 1: Participants randomly assigned to Smart-T will have significantly higher rates of biochemically-verified abstinence than those assigned to QuitGuide at 26 weeks post-quit.
Determine the effect of Smart-T treatment messages on key lapse risk factors. Hypothesis 2: Smoking urge, stress, and cigarette availability will decline more and cessation motivation will increase more following tailored messages that target these lapse triggers in real-time (Smart-T condition) compared with similar situations wherein no messages are provided (QuitGuide condition).
EXPERIMENTAL DESIGN:
Participants (N=550) will be recruited through the TSET Health Promotion Research Center (HPRC) Tobacco Treatment Research Program (TTRP) which is directed by Dr. Darla Kendzor (Co-I). Participants will also be recruited through advertisements. Individuals seeking smoking cessation services at the TTRP will be given a verbal description of the study during their first visit, and those interested will be screened for study eligibility. Those who respond to study advertisements will complete a brief RedCap screener online (i.e., OKSmokerstudy.com), and those who qualify for the study will contacted by study staff and scheduled for a screening/baseline visit. Consistent with our previous research with low SES populations, we have limited exclusion criteria so that the sample is as broad and representative of the population as possible. Interested individuals will be included in the study if they: 1) earn a score ≥ 4 on the Rapid Estimate of Adult Literacy in Medicine-Short Form (REALM-SF)56 indicating > 6th grade English literacy level (required to complete EMAs; at least 88% of all individuals screened for our EMA studies have met this inclusion criterion), 2) are willing to quit smoking 7 days after the baseline assessment, 3) are ≥ 18 years of age, 4) have an expired CO level ≥ 7 ppm suggestive of current smoking for those who attend in person baseline visits or substantiate smoking status (e.g., produce a pack of cigarettes) during baseline assessments by sending picture of cigarettes to staff 5) are currently smoking ≥ 5 cigarettes per day, 6) have no contraindications to using NRT, 7) agree to complete EMAs and CO tests on a study provided or personal smartphone, 8) have household income < 200% of the federal poverty guideline,57 and 9) agree to complete the 26 week post-quit follow-up assessment over the phone and via EMA.
Eligible and interested individuals will be randomized to 1 of 2 groups: 1) Smart-T smoking cessation intervention plus NRT, or 2) NCI QuitGuide smoking cessation intervention plus NRT. Stratified randomization will be used to assign participants to groups based upon race, sex, and cigarettes smoked per day. Participants will be followed for 27 weeks and will attend either 1 in-person visit or complete phone-based baseline visits. Participants will be prompted to complete daily EMAs and tests of smoking status using a portable, low-cost, carbon monoxide monitor (Bedfont iCO Smokerlyzer) on 3 days each week. This data will be used to address primary (i.e., biochemically verified 7-day point prevalence abstinence at 26 weeks post-quit) and secondary outcomes (e.g., 30-day point prevalence abstinence, number of days to first lapse, longest period of smoking abstinence). Geographic location data will be captured multiple times per day to link characteristics of the present environment (e.g., proximity to tobacco outlets) with cessation-related outcomes. We have already created software that integrates the iCO sensor into our InsightTM mobile application platform.
Sub-Study Update: A sample(n=30) of American Indian/Alaska Native participants who have completed the 6 month follow-up assessment will be asked to participate in another qualitative interview designed to assess the perceived utility and cultural fit of the Smart-T App.Information gathered from these qualitative interviews will be used to culturally modify and then experimentally test a new, culturally tailored, version of the Smart-T app for AI/AN smokers who want to quit smoking. In addition, this will serve as an incredibly valuable training opportunity for an emerging Native American scientist to learn tobacco cessation, mHealth, and qualitative methods research from an interdisciplinary team of leading experts in the field.
PROPOSED PROCEDURE:
Individuals who provide informed consent and meet the study inclusion criteria will complete the baseline assessment in TTRP clinic space (the TTRP is located in Research Parkway in a building that is adjacent to the PI's office). Participants may alternatively complete the baseline assessment via phone calls with study staff. Following the baseline assessment, participants will be given instruction on how to complete phone-based EMAs and carbon monoxide assessments. All participants, regardless of condition, will be compensated for completing the baseline assessments, phone-based follow-up, and EMAs. In addition, participants will complete expired breath carbon monoxide tests using the portable iCO device 3 days per week (weeks 1-27).
Baseline and follow-up measures will assess demographic and smoking characteristics, multiple constructs that are known to be related to lapse (e.g., depression, stress, affect, social support), and document intervention effects (See Table 3 and Appendix). We will also access participant perceptions of each app feature. The Baseline process will take approximately 60-90 minutes to complete and data will be collected either on laptop/tablet computers using Questionnaire Development System (QDS) software or remotely via RedCap surveys. QDS uses a computer-administered self-interview format (i.e., ACASI), which reduces data entry errors and the need to retain paper copies of raw data. Each item appears on the computer screen while the program simultaneously reads the item (participants touch the screen to select answers only after QDS reads each item). Participants wear headphones so that others do not hear the survey items. Participants from our previous studies in similar populations, including those with no computer experience, have reported few problems using the QDS program. Staff will be available to help participants who may have difficulty. The RedCap surveys have been designed to replicate the QDS version as closely as possible. The 26 week post-quit follow-up assessment, which includes a longer EMA (i.e., 20-30 minutes) and a phone call based interview (i.e., The Treatment Improvement Survey, 10-15 minutes) that will be recorded for qualitative analysis.
Participants who own an Android smartphone (OS version 6.0 or higher) will be encouraged to download and use the study app on their own phone. Those who do not own this type of smartphone and those who do not have a data plan will be loaned a Samsung smartphone (or equivalent) for 27 weeks so that they may complete EMAs. Participants will navigate through the EMA program and enter data simply by touching the screen. The study app (i.e., Smart-T app or EMA only app) includes a "Call Staff" function/button that automatically calls study staff (e.g., if they have problems completing EMAs). The EMA app also includes a "Payment" button which, when pressed, indicates the number of EMAs that have been prompted and completed and the current level of compensation based upon the up-to-the-moment percentage of EMAs completed. Smartphones will automatically collect data when on-demand features are accessed for both the QuitGuide and Smart-T groups (e.g., number of times features are used). Use of personal vs. study provided phones will be examined as a covariate in all analyses.
IMPORTANCE OF KNOWLEDGE REASONABLY EXPECTED TO RESULT FROM THE RESEARCH:
Although many smartphone based smoking cessation apps exist, none have been developed and empirically validated via a randomized controlled trial in socioeconomically disadvantaged populations of smokers who are seeking to quit smoking. This study is the next step in a line of research that aims to develop and disseminate effective and automated treatments for smoking cessation for this underserved and understudied population. Thus, the knowledge that will be gained from this study is important. Furthermore, the Smart-T app will allow us to reach a population that frequently lacks access to traditional intervention programs, due to limited availability, income, and/or transportation, among other barriers. In addition, the proposed smartphone app is highly versatile and may be easily modified for use in other populations or communities. The risks to subjects are minimal, especially considering the protections against risks that will be implemented for this study.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Smart-T + NRT | Experimental | Combination Product: Smart-T + NRTSmart-T provides content during the pre-quit and post-quit periods to prepare and support participants during their quit attempt. The Smart-T app contains multiple components including an EMA delivery and data transfer system, automated messages based upon EMA responses, and on-demand content. All participants will receive free nicotine replacement therapy (NRT). |
| NCI QuitGuide + NRT | Active comparator | Combination Product: QuitGuide + NRTThe National Cancer Institute's QuitGuide app is a free smartphone app and is one of few apps that includes many of the recommendations detailed in the Clinical Practice Guideline. The QuitGuide app aims to help smokers understand their smoking patterns and develop the skills needed to quit smoking. QuitGuide provides content during the pre-quit and post-quit periods to prepare and support participants during their quit attempt. All participants will receive free nicotine replacement therapy (NRT). |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- earn a score ≥ 4 on the Rapid Estimate of Adult Literacy in Medicine-Short Form (REALM-SF) indicating > 6th grade English literacy level
- are willing to quit smoking 7 days after the baseline visit
- are ≥ 18 years of age
- have an expired CO level ≥ 8 ppm suggestive of current smoking
- are currently smoking ≥ 5 cigarettes per day
Key exclusion criteria (2 listed)
- cannot read, speak, and understand English
- are < 18 years of age
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Smart-T + NRTSmart-Treatment App and Nicotine Replacement Therapy | Combination product | Smart-T + NRT |
| QuitGuide + NRTNCI QuitGuide Treatment App and Nicotine Replacement Therapy | Combination product | NCI QuitGuide + NRT |
Primary outcome
Biochemically-Verified Smoking Cessation
Time frame: 27 Weeks
Biochemically confirmed 7-day point prevalence abstinence using the CO criteria cutoff of ≤ 6 ppm
4 secondary outcomes
Change in Urge to Quit Smoking
Time frame: 27 weeks
Change in Stress
Time frame: 27 weeks
Change in Perceived Cigarette Availability
Time frame: 27 weeks
Change in Motivation to Quit Smoking
Time frame: 27 weeks
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Aug 2025.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 40810943Hebert ET, Kendzor DE, Vidrine DJ, Langford JS, Kezbers KM, Montgomery A, Chen M, Frank-Pearce SG, Vesely SK, Chen S, Barrett ZCW, Businelle MS. Just-in-Time Adaptive Intervention for Smoking Cessation in Low-Income Adults: A Randomized Clinical Trial. JAMA Netw Open. 2025 Aug 1;8(8):e2526691. doi: 10.1001/jamanetworkopen.2025.26691.
- Individual participant dataSharing planned: No
Related trials for Smoking Cessation
Active, not recruiting
An Interactive Smartphone Application to Motivate Smokers to Quit
Smoking Cessation, Smoking Behaviors
Not yet recruiting
Comparing the Efficacy of a Conversational Agent (QuitBot) Versus Standard Health Education on Smoking Cessation Among Medical Students; A Randomized Controlled Trial.
Conversational Agent, Smoking Cessation
Enrolling by invitationObservational study
Using Smartwatches to Monitor Smoking in Real-life Situations
Smoking
Active, not recruitingPhase 3
Early Withdrawal Exposure and Negative Affect Withdrawal (NAW) Regulation Training for Smoking Cessation
Tobacco Dependence
Active, not recruitingEarly Phase 1
Smoking Cessation Intervention During Low Dose CT (LDCT) Screening for Lung Cancer
Smoking Cessation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Michael S Businelle, PhD principal investigator
University of Oklahoma
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2/3 study testing Smart-T + NRT and QuitGuide + NRT in people with Smoking Cessation, run by University of Oklahoma at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 31 Jul 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Biochemically-Verified Smoking Cessation (time frame: 27 Weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03740490, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Aug 2025.